Cincinnati Children's Hospital Medical Center has received $2.2 million from the National Institutes of Health (NIH) to track children who have rare genetic disorders.
In bid to improve patient adherence, the U.S. National Institutes of Health is funding and helping run two clinical trials of long-acting injectable HIV candidates being developed by Johnson & Johnson's Janssen and GlaxoSmithKline.
Researchers supported by the National Institutes of Health Common Fund's Roadmap Epigenomics Program have successfully mapped the epigenomes of 127 types of human cells and tissues. This bridges the basic charting of the human genome by filling in the specificities on which parts of it are involved in making a particular kind of cell.
The National Center for Complementary and Integrative Health at the National Institutes of Health (NIH) has proposed conducting large research studies of nondrug pain management approaches. It did so in a report by a working group of the Center's Advisory Council.
SAN FRANCISCO--More than a few presentations at the JP Morgan Healthcare conference this week sought to address the future of next-generation sequencing, particularly with the huge waves of related news.
After 14 years of work and $1.2 billion in costs with nothing to show for it, the NIH has decided to cut its blockbuster losses on an ambitious but bungled attempt to study environmental influences on children's health.
The National Institutes of Health recently awarded $20 million to a collaboration of researchers led by the Oak Crest Institute of Science to develop a novel intravaginal ring designed to prevent the spread of sexually transmitted HIV in women by delivering powerful combinations of antiretroviral drugs.
The National Institutes of Health has kicked off the BRAIN Initiative by awarding $46 million to 58 projects. And Google has come on board as a commercial partner to develop software and infrastructure to handle the petabyte-scale data sets the projects are expected to generate.
The National Cancer Institute has launched a three to four year broad-based study of exceptional responders--patients who have had particularly good outcomes on cancer therapies as compared to their peers. The initiative was first considered a few years ago when it started to become easier to determine the molecular basis of why a particular patient's cancer responds to a molecularly targeted drug, but it is only being undertaken now.
The Geneva Foundation, along with partner BioFactura, received a grant of more than $3 million from the U.S. National Institutes of Health to develop an antibody drug to combat the Sudan strain of the ebolavirus.